Bob Henson, weather and climate blogger at Weather Underground, discuss the arctic blast of cold air the United States has seen over the last couple of weeks and the "bomb" cyclone that meteorologists are calling winter storm Grayson.
Henson tells us what a "bomb" cyclone is, noting that "Grayson" is actually a "double bomb" because of the intensity and speed at which the pressure dropped.
We also talk the differences between climate and weather, referencing President Trump's tweet that insinuates that cold weather might be a reason to dismiss climate change is real.
Henson also compares winter storm Grayson to 1993's "Storm of the Century," breaking down the differences and similarities between the two.
Australia’s Great Barrier Reef is spawning in an explosion of color as the World Heritage-listed natural wonder recovers from life-threatening coral bleaching episodes.
Climate change that may have contributed to a lobster boom in Maine could soon lead to a bust. Chloe Aiello reports.
Good Morning America co-host Michael Strahan will be among the crew on Blue Origin’s next flight to space.
President Joe Biden is ordering a record-setting 50 million barrels of oil released from America's strategic reserve to help bring down energy costs.
All the news you Need2Know for Tuesday, November 23, 2021.
The U.S. is moving to open up COVID-19 booster shots to all adults, letting them choose another dose of either the Pfizer or Moderna vaccine.
U.S. health officials say an estimated 100,000 Americans died of drug overdoses in one year. That's a total the nation has never seen.
Russian officials on Tuesday rejected accusations that they endangered astronauts aboard the International Space Station by conducting a weapons test that created more than 1,500 pieces of space junk.
Austria has taken what its leader called the “dramatic” step of implementing a nationwide lockdown for unvaccinated people who haven’t recently had COVID-19.
Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market.
